# Stämm Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stamm-biotech

- Industry: Biotechnology
- Headquarters: Buenos Aires, Argentina
- Website: www.stamm.bio
- Total disclosed funding: $17M
- Latest round: Series A (Jan 27, 2022)
- Investors on record: 11

## About

Stämm Biotech is a biotechnology firm specializing in advanced biomanufacturing solutions for biologics and cell therapies, enhancing production efficiency through innovative automation and AI technologies.Founded in 2014 in Buenos Aires, Argentina, Stämm Biotech focuses on biomanufacturing for biologics and cell therapies. The company has engaged in 6 deals, with its most recent funding round being a Series A. The founders, Federico Vegh and Yuyo Vegh, have experience in launching innovative biotech solutions. In January 2022, Stämm raised USD 17.000 mn in Series A funding led by Varana Capital, with participation from several notable investors. The funding represents the total amount raised by the company thus far.Stämm specializes in advanced biomanufacturing solutions tailored for the production of biologics and cell therapies. The company's core offerings include automated and continuous manufacturing systems that enhance the efficiency and scalability of biologics production, as well as comprehensive support for cell line development aimed at both clinical and commercial manufacturing. Stämm employs AI generative models to create cell-predictive pipelines, leveraging multi-omics biological data to optimize the biomanufacturing process. This innovative approach addresses specific challenges faced by biotechnology firms, pharmaceutical companies, and healthcare organizations, with products deployed across North America, Europe, and Latin America, serving a diverse clientele including research institutions and biotech startups.Stämm generates revenue through structured partnerships and collaborations with clients primarily in the biopharmaceutical sector. The company's business model involves B2B transactions where clients engage in co-development opportunities for advanced biomanufacturing solutions, including project-based contracts with upfront payments for technology implementation and performance-based milestones. The company may also provide subscription-based access to its AI-driven platforms and ongoing support services, focusing on delivering high-value, tailored solutions in the biomanufacturing landscape.Stämm plans to utilize the USD 17.000 mn raised in its Series A funding to prepare for the commercialization of its technology, develop biopharma partnerships into pilot-scale, enhance its operational infrastructure, and expand its team of over 100 individuals. The company aims to deepen its international presence, targeting new markets in North America and Europe by 2024, with a focus on launching upcoming products designed to meet the evolving needs of the biotechnology sector.

## Funding rounds

- Series A, Jan 27, 2022, $17M — SOSV, Draper, IndieBio, GRID EXPONENTIAL, Varana Capital, Decarbonization Consortium, Trillian LLC, VistaEnergy, Teramips Technologies, Serenity Traders, Dragones VC
- Series A, Apr 20, 2021 — Varana Capital
- Seed, Jun 25, 2019 — SOSV, IndieBio
- Seed, Jul 9, 2018 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed, Series A
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed, Series A
- Varana Capital (https://capitalatlas.ai/funds/varana-capital) — Series A
- Draper (https://capitalatlas.ai/funds/draper) — Series A
- GRID EXPONENTIAL (https://capitalatlas.ai/funds/grid-exponential) — Series A
- Decarbonization Consortium — Series A
- Trillian LLC — Series A
- VistaEnergy — Series A
- Teramips Technologies (https://capitalatlas.ai/funds/teramips-technologies) — Series A
- Serenity Traders — Series A
- Dragones VC (https://capitalatlas.ai/funds/dragones-vc) — Series A